DxI 9000 Access platform delivers strong hepatitis B and C serology performance
Serologic diagnosis remains the front line for identifying hepatitis B virus and hepatitis C virus infection, and the analytical demands are exacting. A screening platform must separate true reactivity from background noise, detect infection early enough to matter clinically, and stay reliable across the different markers used to classify acute infection, chronic infection, immunity, and resolved disease. In this evaluation of the DxI 9000 Access Immunoassay Analyzer, investigators tested that promise against established systems using more than 1,000 serum and plasma specimens, including seroconversion panels and clinical samples.
The practical question is straightforward: can a high-throughput analyzer identify the right serologic signals without eroding confidence at the margins where diagnosis is hardest? In hepatitis care, those margins often determine whether a patient is flagged for confirmatory testing, linked to follow-up, or incorrectly reassured. The performance profile reported here suggests the Access assays can function as a serious laboratory option rather than a purely technical competitor.
Anti-HCV detection was strong, but early seroconversion still exposed a lag
The anti-HCV assay achieved 97.5% sensitivity and 97.0% specificity, a level that supports broad clinical use in routine screening and diagnostic workflows. Agreement with comparator platforms was high overall, but some seroconversion panels showed slightly delayed detection. In practical laboratory terms, that delay matters because the earliest antibody responses define the narrowest window for catching new infection before downstream clinical and transmission consequences accumulate.
This is where assay design and biology intersect. Antibody-based hepatitis C testing depends on the host immune response, which does not appear all at once; the assay must identify a rising signal that may still be close to the detection threshold. A platform with strong aggregate sensitivity can still lag in select early samples, and those are the specimens that most often expose the difference between a robust screening tool and a truly responsive one.
HBsAg detection combined high accuracy with broad variant recognition
The HBsAg assay performed particularly well, with 98.8% sensitivity and 99.2% specificity. That profile is clinically important because hepatitis B surface antigen remains one of the most widely used markers for identifying active infection. High specificity reduces unnecessary follow-up work, while high sensitivity minimizes missed cases in screening programs, blood-bank algorithms, and clinical triage.
Equally relevant, the analyzer showed robust detection of most HBsAg variants. Hepatitis B is not a static target, and assay performance can be strained when circulating antigenic forms differ from the canonical sequences used in platform design. Broad recognition of variants strengthens confidence that the system is not narrowly tuned to one laboratory idealization of the virus, but instead remains useful against biologic diversity encountered in real-world testing.
Anti-HBc and anti-HBs results tracked closely with established systems
The anti-HBc assays, both total and IgM, reached 100% sensitivity and showed excellent concordance across platforms. That result is especially relevant because core antibody testing helps distinguish past exposure from active or recent infection, depending on the assay format and clinical context. In hepatitis B diagnostics, a marker that misses positives can distort the entire interpretive pathway, particularly when used alongside HBsAg and anti-HBs.
Anti-HBs testing also showed good agreement, although minor discrepancies appeared in samples with low titers below 10 mIU/mL. Low-level titers are a familiar problem in serology because they sit near the threshold where assay precision and calibration differences become visible. For clinicians, those borderline values often drive decisions about vaccine response, susceptibility, and the need for additional evaluation, so even small inter-platform differences deserve attention.
A single numeric threshold can reshape interpretation at the bedside.
Agreement across platforms was generally high, but border-zone samples still matter
Across the evaluated markers, agreement with comparator assays ranged from 84.7% to 100%. That span reflects the reality of multiplex serology: some targets line up almost perfectly, while others become more variable at low signal intensity or during early immune conversion. In a laboratory setting, this is not a trivial statistical footnote. Border-zone samples are exactly where clinicians rely on the analyzer to preserve diagnostic continuity rather than introduce uncertainty.
The broader clinical value of this study lies in the combination of strong accuracy metrics and broad concordance across established systems such as VITROS ECiQ and Alinity i. Compatibility with existing workflows matters because hepatitis testing is often embedded in high-volume services where turnaround time, stability, and inter-platform comparability shape operational decisions. A new analyzer does not need perfection to be useful, but it does need to prove that its results can be trusted when they are routed into existing diagnostic pathways.
What the performance profile means for hepatitis testing laboratories
The findings position the DxI 9000 Access system as a credible platform for serologic testing of viral hepatitis B and C. Its strongest showings came in HBsAg and anti-HBc testing, where sensitivity, specificity, and concordance were all high. Anti-HCV performance was also solid, with the caveat that some seroconversion panels were detected slightly later than on comparator systems. Anti-HBs results were generally reliable, though low-titer samples remained an area where minor discrepancies appeared.
From a pathophysiologic standpoint, those results fit the biology of hepatitis serology. Surface antigen detection requires faithful recognition of circulating viral protein; core antibody reflects host exposure and immune memory; antibody to hepatitis C depends on the timing of seroconversion; and surface antibody can become difficult to interpret when levels hover close to the cutoff. A platform that performs well across all four markers has obvious value in screening, confirmation, and follow-up testing.
The study was supported by assays provided by Beckman Coulter, and the authors reported no known competing financial interests or personal relationships. Even with those safeguards, the most important remaining question is operational rather than conceptual: how will the DxI 9000 Access platform perform in day-to-day use across different laboratories, specimen mixes, and prevalence settings where predictive value can shift with the population being tested?